Literature DB >> 23262667

Restoring neuroprotection through a new preclinical paradigm: translational success for NA-1 in stroke therapy.

Ryan Instrum1, Hong-shuo Sun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23262667      PMCID： PMC4086500          DOI： 10.1038/aps.2012.175

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   6.150


× No keyword cloud information.
  10 in total

1.  Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.

Authors:  Michelle Aarts; Yitao Liu; Lidong Liu; Shintaro Besshoh; Mark Arundine; James W Gurd; Yu-Tian Wang; Michael W Salter; Michael Tymianski
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

2.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

3.  Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain.

Authors:  Douglas J Cook; Lucy Teves; Michael Tymianski
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962

4.  Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Michael D Hill; Renee H Martin; David Mikulis; John H Wong; Frank L Silver; Karel G Terbrugge; Geneviève Milot; Wayne M Clark; R Loch Macdonald; Michael E Kelly; Melford Boulton; Ian Fleetwood; Cameron McDougall; Thorsteinn Gunnarsson; Michael Chow; Cheemun Lum; Robert Dodd; Julien Poublanc; Timo Krings; Andrew M Demchuk; Mayank Goyal; Roberta Anderson; Julie Bishop; David Garman; Michael Tymianski
Journal:  Lancet Neurol       Date:  2012-10-08       Impact factor: 44.182

5.  Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein.

Authors:  R Sattler; Z Xiong; W Y Lu; M Hafner; J F MacDonald; M Tymianski
Journal:  Science       Date:  1999-06-11       Impact factor: 47.728

6.  Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor.

Authors:  Bernt T Bråtane; Hong Cui; Douglas J Cook; James Bouley; Michael Tymianski; Marc Fisher
Journal:  Stroke       Date:  2011-09-08       Impact factor: 7.914

7.  1,026 experimental treatments in acute stroke.

Authors:  Victoria E O'Collins; Malcolm R Macleod; Geoffrey A Donnan; Laura L Horky; Bart H van der Worp; David W Howells
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

8.  A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates.

Authors:  Douglas J Cook; Lucy Teves; Michael Tymianski
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

Review 9.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

Authors:  Chrysanthy Ikonomidou; Lechoslaw Turski
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

10.  Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat.

Authors:  Hong-Shuo Sun; Tracy A Doucette; Yitao Liu; Yuan Fang; Lucy Teves; Michelle Aarts; Catherine L Ryan; Paul B Bernard; Anthony Lau; Joan P Forder; Michael W Salter; Yu Tian Wang; R Andrew Tasker; Michael Tymianski
Journal:  Stroke       Date:  2008-07-10       Impact factor: 7.914
  10 in total
  4 in total

Review 1.  Targeting Reperfusion Injury in the Age of Mechanical Thrombectomy.

Authors:  Atsushi Mizuma; Je Sung You; Midori A Yenari
Journal:  Stroke       Date:  2018-05-14       Impact factor: 7.914

2.  Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies.

Authors:  Diego Milani; Megan C Bakeberg; Jane L Cross; Vince W Clark; Ryan S Anderton; David J Blacker; Neville W Knuckey; Bruno P Meloni
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

3.  Poly-arginine-18 peptides do not exacerbate bleeding, or improve functional outcomes following collagenase-induced intracerebral hemorrhage in the rat.

Authors:  Lane Liddle; Ryan Reinders; Samantha South; David Blacker; Neville Knuckey; Frederick Colbourne; Bruno Meloni
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

4.  Inhibition of the AMPK/nNOS pathway for neuroprotection in stroke.

Authors:  Mushfiquddin Khan; Inderjit Singh
Journal:  Neural Regen Res       Date:  2016-03       Impact factor: 5.135
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.